查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1404714

美國顯影劑市場規模、佔有率和趨勢分析報告：按模式、類型、應用和細分市場預測，2023-2030 年

U.S. Contrast Media Market Size, Share & Trends Analysis Report By Modality (Modality, Ultrasound, Magnetic Resonance Imaging (MRI), X-ray/Computed Tomography (CT Scan)), By Type, By Application, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 94 Pages | 商品交期: 2-10個工作天內

價格

美國顯影劑市場的成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計2030年美國顯影劑市場規模將達33.6億美元，2023年至2030年複合年成長率為4.1%。

慢性病負擔的增加正在創造對診斷影像的需求，從而推動市場成長。 MRI 等影像檢查已成為大多數疾病診斷的關鍵，影像技術在醫療保健領域的大規模滲透正在推動美國市場對顯影劑的需求。癌症和糖尿病等慢性疾病正在迅速成為主要的公共衛生問題，並且是美國各地的主要原因之一，因此需要早期診斷工具和有效的治療方案。

因此，複雜合併症和長期疾病的盛行率不斷增加是影像檢查和顯影劑的主要促進因素之一，促進了市場成長。由於就診患者減少，COVID-19 疫情對市場產生了負面影響。在許多放射科，診斷影像病例數迅速減少。然而，美國許多州已經開始重新開放經濟。然而，顯影劑使用率要達到疫情前的水平還需要一段時間。此外，由於COVID-19疫苗的發布和監管的放鬆，原料進出口已恢復。預計這將推動預測期內的市場成長。

美國顯影劑市場報告亮點

  • MRI 等影像檢查對於大多數疾病的診斷至關重要，影像技術在醫療保健領域的大規模普及正在推動美國市場對顯影劑的需求。
  • 碘顯影劑由於與其他造影劑相比具有優越的滲透性和低毒性，在市場顯影劑佔據主導地位，到 2022 年將佔據最大佔有率，超過 60%。
  • X光/CT細分市場佔據主導地位，2022年佔最大佔有率，約65%。 X 光/CT 模式的廣泛接受度和成本效益正在推動該模式採用顯影劑。
  • 對診斷影像的需求不斷成長，促使顯影劑製造商進行廣泛的研究和開發工作，以將新產品推向市場並獲得新適應症的核准。
  • 例如，2021 年，Bracco 的 20 瓶裝 Lumason（一種超音波顯影劑）獲得美國FDA核准。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章美國顯影劑市場變數、趨勢、範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 普及和成長前景圖
  • 市場動態
    • 市場促進因素分析
    • 市場抑制因素分析
  • 美國顯影劑市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章美國顯影劑：類型估計與趨勢分析

  • 美國顯影劑市場，按類型分類的要點
  • 美國顯影劑市場：2022 年和 2030 年趨勢與市場佔有率分析
  • 微氣泡顯影劑
  • 钆基顯影劑
  • 碘顯影劑
  • 鋇顯影劑

第5章美國顯影劑：模態估計與趨勢分析

  • 美國顯影劑市場，按模式分類的要點
  • 美國顯影劑市場：2022 年和 2030 年趨勢與市場佔有率分析
  • 超音波
  • 磁振造影(MRI)
  • X 光/電腦斷層掃描（電腦斷層掃描）

第6章美國顯影劑：使用估計和趨勢分析

  • 美國顯影劑市場，按應用分類的要點
  • 美國顯影劑市場：2022 年和 2030 年趨勢與市場佔有率分析
  • 心血管
  • 神經系統疾病
  • 胃腸道疾病
  • 癌症
  • 腎臟疾病
  • 肌肉骨骼疾病
  • 其他

第7章競爭形勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭分類
    • Bayer AG
    • GE Healthcare
    • Guerbet
    • Lantheus Medical Imaging, Inc
    • Bracco Diagnostic Inc
    • Trivitron Healthcare
    • Nano Therapeutics Pvt Ltd.
    • IMAX Diagnostic Imaging
    • CMC Contrast AB (ASCELIA PHARMA AB)
Product Code: GVR-4-68039-917-4

U.S. Contrast Media Market Growth & Trends:

The U.S. contrast media market size is expected to reach USD 3.36 billion by 2030, registering a CAGR of 4.1% from 2023 to 2030, according to a new report by Grand View Research, Inc. The increasing burden of chronic diseases is creating a demand for diagnostic imaging procedures, which, in turn, is driving the market growth. Imaging tests, such as MRI, have become an integral part of the diagnosis for most diseases, and large-scale penetration of imaging technology in healthcare has increased the demand for contrast media in the U.S. market. Chronic diseases, such as cancer and diabetes, are rapidly becoming a major public health concern and are among the leading causes of death across the U.S., resulting in the need for early diagnostic tools and effective treatment options.

Hence, the increasing prevalence of complex comorbidities and long-term diseases is one of the major drivers of imaging tests and contrast agents; thus, contributing to the market growth. The COVID-19 outbreak had a negative impact on the market due to decreased patient visits to hospitals. Many radiology departments experienced a rapid decline in imaging case volume. However, many states in the U.S. have begun to reopen their economies; however, it will take time for the utilization rate of contrast media to reach pre-pandemic levels. In addition, with the launch of COVID-19 vaccines and ease in restrictions, the import and export of raw materials have resumed. This, in turn, therefore, is expected to boost the market growth over the forecast period.

U.S. Contrast Media Market Report Highlights:

  • Imaging tests, such as MRI, have become an integral part of the diagnosis for most diseases, and large-scale penetration of imaging technology in healthcare has increased the demand for contrast media in the U.S. market
  • The iodinated contrast media dominated the market and held the largest market share of over 60% in 2022 on account of excellent radio-opacity and low toxicity of iodinated contrast media than other agents
  • The X-ray/CT segment dominated the market and held the largest market share of around 65% in 2022. Wide acceptance and cost-efficiency of X-ray/CT modality boost the adoption of contrast agents for this modality
  • The rising demand for imaging procedures has resulted in extensive R&D activities by contrast media manufacturers to launch novel products in the market and to get approved for new indications
  • For instance, in 2021, Bracco got the U.S. FDA approval for 20-vial pack configuration of Lumason, which is an ultrasound contrast media agent

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Type
    • 1.1.2. Modality
    • 1.1.3. Application
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. Modality outlook
    • 2.2.3. Application outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Contrast Media Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. U.S. Contrast Media Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. U.S. Contrast Media: Type Estimates & Trend Analysis

  • 4.1. U.S. Contrast Media Market, By Type Key Takeaways
  • 4.2. U.S. Contrast Media Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Microbubble Contrast Media
    • 4.3.1. Microbubble contrast media market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Gadolinium-based Contrast Media
    • 4.4.1. Gadolinium-based contrast media market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Iodinated Contrast Media
    • 4.5.1. Iodinated contrast media market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.6. Barium-based Contrast Media
    • 4.6.1. Barium-based contrast media market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. U.S. Contrast Media: Modality Estimates & Trend Analysis

  • 5.1. U.S. Contrast Media Market, By Modality Key Takeaways
  • 5.2. U.S. Contrast Media Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Ultrasound
    • 5.3.1. Ultrasound market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Magnetic Resonance Imaging (MRI)
    • 5.4.1. Magnetic resonance (MRI) imaging market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. X-RAY/Computed Tomography (CT Scan)
    • 5.5.1. X-RAY/computed tomography (CT Scan) market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. U.S. Contrast Media: Application Estimates & Trend Analysis

  • 6.1. U.S. Contrast Media Market, By Application Key Takeaways
  • 6.2. U.S. Contrast Media Market: Movement & Market Share Analysis, 2022 & 2030
  • 6.3. Cardiovascular
    • 6.3.1. Cardiovascular market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.4. Neurological Disorders
    • 6.4.1. Neurological disorders market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.5. Gastrointestinal Disorders
    • 6.5.1. Gastrointestinal disorders market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.6. Cancer
    • 6.6.1. Cancer market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.7. Nephrological Disorders
    • 6.7.1. Nephrological disorders market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.8. Musculoskeletal Disorders
    • 6.8.1. Musculoskeletal disorders market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.9. Others
    • 6.9.1. Others market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
    • 7.2.1. Bayer AG
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. GE Healthcare
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Guerbet
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Lantheus Medical Imaging, Inc
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. Bracco Diagnostic Inc
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. Trivitron Healthcare
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Nano Therapeutics Pvt Ltd.
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. IMAX Diagnostic Imaging
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. CMC Contrast AB (ASCELIA PHARMA AB)
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Product benchmarking
      • 7.2.9.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 U.S. U.S. contrast media market, by type, 2018 - 2030 (USD Million)
  • Table 3 U.S. U.S. contrast media market, by modality, 2018 - 2030 (USD Million)
  • Table 4 U.S. U.S. contrast media market, by application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 U.S. contrast media: Market outlook
  • Fig. 9 U.S. contrast media: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 U.S. contrast media market driver impact
  • Fig. 15 U.S. contrast media market restraint impact
  • Fig. 16 U.S. contrast media market strategic initiatives analysis
  • Fig. 17 U.S. contrast media market: Type movement analysis
  • Fig. 18 U.S. contrast media market: Type outlook and key takeaways
  • Fig. 19 Microbubble Contrast Media market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Gadolinium-based Contrast Media market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Iodinated Contrast Media market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Barium-based Contrast media market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 U.S. contrast media market: Modality movement analysis
  • Fig. 25 U.S. contrast media market: Modality outlook and key takeaways
  • Fig. 26 Ultrasound market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Magnetic resonance imaging (MRI) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 X-ray/computed tomography (CT scan) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 U.S. contrast media market: Application movement analysis
  • Fig. 30 U.S. contrast media market: Application outlook and key takeaways
  • Fig. 31 Cardiovascular conditions market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Neurological disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Gastrointestinal disorders management market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Nephrological disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Musculoskeletal disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Others market estimates and forecasts, 2018 - 2030 (USD Million)